RecruitingPhase 4

Anesthesia and Non-small Cell Lung Cancer Recurrence

South Korea5,384 participantsStarted 2024-08-05

Plain-language summary

There has been ongoing debate about the relationship between cancer recurrence and anesthetic management. Therefore, the investigators will test the hypothesis that the recurrence free survival (RFS) after curative resection of NSCLC is higher in patient who received total intravenous anesthesia (TIVA) than volatile anesthetics in this multi-center randomized trials.

Who can participate

Age range

19 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * American Society of Anesthesiologists physical status (ASA) Ⅰ-Ⅲ * The Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Lung resection surgery (segmentectomy, lobectomy, bilobectomy, pneumonectomy; video-assisted, robot-assisted, or open) with curative intent for NSCLC (clinical Tumor, Node, Metastasis (TNM) stage Ⅰ- ⅢA). Exclusion Criteria: * Distant metastasis or malignant tumor in other organs that according to the attending surgeon is not in long-term remission * Severe neurologic conditions * Severe hepatic disease (Child-Pugh classification C) * Renal failure requiring renal replacement therapy * History of anesthesia and/or surgery within 1 yr * Previous surgery due to lung cancer (except diagnostic biopsies) * Contraindications to any study medication (history of allergy, hypersensitivity reaction, or any other contraindication) * Planned joint extrapulmonary procedure * Surgery under cardiopulmonary bypass or extracorporeal membrane oxygenation * Postoperative sedation * Pregnancy, or lactation * Patient refusal.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Recurrence free survival

Timeframe: Within 3 year after curative resection for NSCLC

Trial details

NCT IDNCT06330038

SponsorSamsung Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-12-31

Contact for this trial

Jeayoun Kim, MD

8234106590 jeayoun.kim@samsung.com

View on ClinicalTrials.gov More Non-small Cell Lung Cancer trials